Cosmos Health Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在藥品行業排名124/158位。機構持股佔比非常高,近一個月多位分析師給出公司評級為。最高目標價3.00。中期看,股價處於下降通道。近一個月,市場表現非常差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。
Cosmos Health Inc評分
相關信息
行業排名
124 / 158
全市場排名
404 / 4582
所屬行業
藥品
壓力支撐
由於公司未披露,未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
0
分析師
--
評級
3.000
目標均價
+511.87%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議
Cosmos Health Inc亮點
亮點風險
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
公司代碼COSM
公司Cosmos Health Inc
CEOSiokas (Grigorios)
網址https://www.cosmosholdingsinc.com/
常見問題
Cosmos Health Inc(COSM)的當前股價是多少?
Cosmos Health Inc(COSM)的當前股價是 0.487。
Cosmos Health Inc 的股票代碼是什麼?
Cosmos Health Inc的股票代碼是COSM。
Cosmos Health Inc股票的52週最高點是多少?
Cosmos Health Inc股票的52週最高點是1.320。
Cosmos Health Inc股票的52週最低點是多少?
Cosmos Health Inc股票的52週最低點是0.280。
Cosmos Health Inc的市值是多少?
Cosmos Health Inc的市值是15.52M。
Cosmos Health Inc的淨利潤是多少?
Cosmos Health Inc的淨利潤為-22.38M。
現在Cosmos Health Inc(COSM)的股票是買入、持有還是賣出?
根據分析師評級,Cosmos Health Inc(COSM)的總體評級為--,目標價格為3.000。